National and Kapodistrian University of Athens
Επίδραση του σακχαρώδους διαβήτη και της αρτηριακής υπέρτασης στη γονιδιακή έκφραση του VEGF (αγγειακός ενδοθηλιακός αυξητικός παράγοντας) και της ενδοθηλίνης 1 στα αγγεία και το μυοκάρδιο
Abstract
dc:descriptionDiabetes is a widespread disease with multiple complications that affect both the microvasculature and the macrovasculature. Over the past decade, dramatic progress has been achieved in elucidating the fundamental processes underlying the pathogenesis of these complications. It is now believed that vascular endothelial growth factor (VEGF), a key regulator of angiogenesis, and endothelin-1 (ET-1), one of the most potent vasoconstrictors in the complex but well-balanced regulation of vascular tone, both play a seminal role in the pathogenesis of chronic diabetic complications. Therefore, the aim of the present study was to develop sensitive, accurate and reproducible real-time PCR assays for the quantification of mRNA expression levels of VEGF, VEGF splice variants (VEGF121, VEGF145, VEGF148, VEGF165, VEGF183 and VEGF189), VEGFRs (VEGFR-1 and VEGFR-2), as well as ET-1, ETaR and ETbR; and to apply these assays for the quantification of the genes of interest in specimens of human atrial myocardium and left internal mammary artery (LIMA) collected from diabetic and non-diabetic patients with coronary artery disease undergoing coronary artery bypass graft surgery. Our results show that the expression of the investigated genes is regulated differently by the presence of diabetes and hypertension in the different tissues. In right atrium specimens, diabetes was independently negatively correlated with total VEGF expression, whereas mRNA levels of total VEGF, VEGF121 and VEGF165 were upregulated in LIMA specimens originating from diabetic patients compared to non-diabetic controls. In both tissue types a strong negative correlation was observed between total VEGF expression and cholesterol blood levels. mRNA expression of VEGFRs was similar between diabetic and non-diabetic tissues. The relative expression of VEGF splice variants as part of the total VEGF message varied significantly between the investigated tissues. VEGF165 was the major splice variant expressed in left atrium, followed by VEGF121 and VEGF189 (59.1±7.7%, 19.2±7.7% and 18.3±5.5% respectively), while in LIMA VEGF121 and VEGF165 were expressed in similar amounts followed by VEGF189 (46.5±11.9%, 40.1±10.9% and 11.5±4.4% respectively). ET-1 copy numbers were lower in atrium samples derived from diabetics patients compared to non-diabetics, but no differences were observed for ETaR or ETbR expression. Significant negative correlations were found between ETaR or ETbR expression in right atrium and cholesterol blood levels. In LIMA specimens, significantly higher ETaR mRNA levels were found in non-diabetic vs. diabetic patients (diabetes was independently negatively correlated with ETaR mRNA expression), whereas there was a similar trend for ET-1 expression which did not reach statistical significance. LIMA samples derived from hypertensive patients displayed higher ET-1, ETaR and ETbR copy numbers compared to normotensive individuals, and for ET-1 and ETbR hypertension was found to be independently correlated to their expression. ET-1 mRNA levels were significantly higher in LIMA compared to paired left atrium specimens, the opposite was true for ETbR, while for ETaR no difference was found between paired tissues. Finally, it must also be noted that, total VEGF expression was independently correlated with ET-1, ETaR or ETbR expression in right atrium but this was not the case for LIMA samples. To our knowledge, this is the first time the expression of VEGF, VEGF splice variants (VEGF121, VEGF145, VEGF148, VEGF165, VEGF183 and VEGF189), VEGF receptors (VEGFR-1 and VEGFR-2), ET-1 and its receptors ΕΤa and ETb is quantified in cardiac and vascular tissue using real-time PCR. Our results indicate that the VEGF and the ET-1 system are affected differently by the presence of diabetes and hypertension and that the effect of these factors is also dependent on the tissue investigated. We believe these findings could help elucidate the biological role of the VEGF and the ET-1 system in the pathogenesis of chronic diabetic complications, and that the assays developed herein are a useful tool for the study of the VEGF and the ET-1 system in various physiologic and pathologic conditions.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zygalaki, Eleni
- Ζυγαλάκη, Ελένη
Subjects
dc:subject × 18- Αγγειακός ενδοθηλιακός αυξητικός παράγοντας (VEGF)
- Ενδοθηλίνη-1 (ΕΤ-1)
- Διαβήτης
- Υπέρταση
- Αγγεία
- Μυοκάρδιο
- Γονιδιακή έκφραση
- VEGF ( Vascular endothelium growth factor)
- Endothelin-1
- Diabetes
- Hypertension
- Vessels
- Myocardium
- Gene expression
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/22150